RLYB
Rallybio Corporation NASDAQ Listed Jul 29, 2021$14.66
After hrs
$14.46
+0.56%
Mkt Cap $77.5M
52w Low $2.16
95.1% of range
52w High $15.31
50d MA $9.19
200d MA $6.00
P/E (TTM)
-5.9x
EV/EBITDA
0.0x
P/B
0.9x
Debt/Equity
0.0x
ROE
-15.5%
P/FCF
-1.0x
RSI (14)
—
ATR (14)
—
Beta
-1.20
50d MA
$9.19
200d MA
$6.00
Avg Volume
146.7K
Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody which is in Phase II clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT. The company is also developing RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. It entered into a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases; and collaboration agreement with Johnson & Johnson to provide pregnant individuals therapeutic solutions at risk of fetal and neonatal alloimmune thrombocytopenia. The company was founded in 2018 and is headquartered in New Haven, Connecticut.
234 Church Street · New Haven, CT 06510 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 12, 2026 | AMC | -1.24 | -1.28 | -3.2% | 9.60 | -0.2% | -1.0% | -2.0% | +0.5% | -2.5% | -5.3% | — |
| Nov 6, 2025 | AMC | -0.25 | -0.14 | +44.0% | 5.11 | -2.9% | -2.2% | +1.8% | +10.4% | +9.4% | +2.7% | — |
| Aug 7, 2025 | AMC | -0.20 | -0.22 | -12.8% | 4.09 | +1.2% | +3.9% | -2.7% | -1.5% | +4.6% | +6.8% | — |
| May 8, 2025 | AMC | -0.21 | -0.21 | +0.0% | 2.34 | +0.0% | +0.0% | +3.0% | +1.7% | +6.0% | +9.4% | — |
| Mar 13, 2025 | AMC | -0.27 | -0.25 | +7.4% | 5.25 | -2.1% | -3.6% | -2.1% | +12.0% | +11.0% | +6.7% | — |
| Nov 7, 2024 | AMC | -0.36 | -0.26 | +27.8% | 7.92 | +0.0% | +1.0% | +6.1% | +12.1% | +10.1% | +2.0% | — |
| Aug 8, 2024 | AMC | -0.42 | -0.37 | +11.9% | 9.52 | +3.4% | -4.2% | -7.6% | -4.2% | -8.4% | -6.7% | — |
| May 9, 2024 | AMC | -0.50 | -0.47 | +6.0% | 15.20 | +2.1% | -3.7% | -6.3% | -3.2% | +0.5% | -2.1% | — |
| Mar 12, 2024 | AMC | -0.44 | -0.50 | -13.6% | 13.44 | +1.8% | +4.8% | -4.8% | -3.6% | -3.0% | -4.8% | — |
| Nov 9, 2023 | AMC | -0.51 | -0.45 | +11.8% | 24.32 | -0.3% | -5.6% | -16.4% | -21.4% | -23.2% | -34.7% | — |
| Aug 8, 2023 | AMC | -0.48 | -0.46 | +4.2% | 42.24 | +0.0% | -0.4% | +6.1% | +9.8% | +13.6% | +13.4% | — |
| May 9, 2023 | AMC | -0.50 | -0.43 | +14.0% | 44.64 | +3.8% | -5.9% | -8.2% | -6.6% | -2.5% | -1.4% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 15 | Jones Trading | Downgrade | Buy → Hold | — | $2.16 | $2.10 | -2.8% | -2.8% | -6.9% | -7.4% | -1.9% | +5.1% |
| Apr 9 | HC Wainwright & Co. | Downgrade | Buy → Neutral | — | $2.00 | $1.80 | -10.0% | +0.0% | +0.0% | +0.0% | +8.0% | +5.0% |
| Mar 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.06 | $5.08 | +0.4% | +1.6% | +16.2% | +15.2% | +10.7% | +5.9% |
| Feb 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.97 | $5.84 | -2.2% | -2.8% | +5.2% | +1.0% | -1.5% | +3.0% |
| Jan 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.52 | $7.52 | +0.0% | -1.9% | -5.3% | -4.3% | -5.3% | -6.9% |
| Dec 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.04 | $9.12 | +0.9% | -6.2% | -3.5% | -6.2% | -6.2% | +2.7% |
| Nov 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.91 | $8.00 | +1.1% | +3.2% | +6.2% | +9.2% | +11.3% | +18.3% |
| Nov 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.92 | $7.92 | +0.0% | +1.0% | +6.1% | +12.1% | +10.1% | +2.0% |
| Oct 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.16 | $8.08 | -1.0% | +0.0% | +1.0% | -1.0% | +0.0% | +0.0% |
| Oct 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.36 | $9.36 | +0.0% | -4.3% | -6.8% | -6.0% | -5.1% | -3.4% |
| Sep 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.20 | $9.20 | +0.0% | -4.3% | -3.5% | -3.5% | -4.3% | -3.5% |
| Aug 26 | Evercore ISI | Maintains | Outperform → Outperform | — | $9.04 | $9.12 | +0.9% | +0.9% | +9.7% | +2.7% | +5.3% | +1.8% |
| Aug 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.12 | $9.28 | +1.8% | -3.5% | +0.0% | -4.4% | -2.6% | -3.5% |
| May 15 | JP Morgan | Downgrade | Overweight → Neutral | — | $14.72 | $14.24 | -3.3% | +3.8% | +1.1% | -3.8% | -13.6% | -12.5% |
| May 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $15.20 | $15.52 | +2.1% | -3.7% | -6.3% | -3.2% | +0.5% | -2.1% |
| Apr 19 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $13.36 | $13.20 | -1.2% | +5.4% | +6.0% | +4.2% | -5.4% | -1.2% |
| Apr 18 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $14.08 | $14.40 | +2.3% | -5.1% | +0.0% | +0.6% | -1.1% | -10.2% |
| Apr 11 | Wedbush | Maintains | Outperform → Outperform | — | $13.04 | $26.64 | +104.3% | +82.8% | +35.0% | +12.3% | +10.4% | +8.0% |
| Mar 13 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $13.44 | $13.68 | +1.8% | +4.8% | -4.8% | -3.6% | -3.0% | -4.8% |
| Mar 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.44 | $13.68 | +1.8% | +4.8% | -4.8% | -3.6% | -3.0% | -4.8% |
| Feb 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $12.40 | $12.72 | +2.6% | +9.0% | +10.3% | +14.2% | +7.1% | +8.4% |
| Feb 7 | Wedbush | Maintains | Outperform → Outperform | — | $12.40 | $12.72 | +2.6% | +9.0% | +10.3% | +14.2% | +7.1% | +8.4% |
| Feb 7 | Jefferies | Downgrade | Buy → Hold | — | $12.40 | $12.72 | +2.6% | +9.0% | +10.3% | +14.2% | +7.1% | +8.4% |
| Feb 7 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $12.40 | $12.72 | +2.6% | +9.0% | +10.3% | +14.2% | +7.1% | +8.4% |
| Dec 21 | Evercore ISI | Maintains | Outperform → Outperform | — | $22.00 | $22.00 | +0.0% | -5.1% | -4.0% | -4.4% | -5.5% | -9.1% |
| Nov 29 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $16.56 | $16.80 | +1.4% | -5.3% | -7.7% | +7.7% | +27.5% | +22.7% |
| Nov 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $24.32 | $24.24 | -0.3% | -5.6% | -16.4% | -21.4% | -23.2% | -34.7% |
| Nov 10 | Wedbush | Maintains | Outperform → Outperform | — | $24.32 | $24.24 | -0.3% | -5.6% | -16.4% | -21.4% | -23.2% | -34.7% |
| Sep 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $43.28 | $43.60 | +0.7% | +0.4% | +0.4% | -2.0% | -1.7% | -1.1% |
| Sep 5 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $43.28 | $43.60 | +0.7% | +0.4% | +0.4% | -2.0% | -1.7% | -1.1% |
| Aug 10 | JP Morgan | Maintains | Overweight → Overweight | — | $42.08 | $42.08 | +0.0% | +6.5% | +10.3% | +14.1% | +13.9% | +3.2% |
| Jul 25 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $47.52 | $47.20 | -0.7% | -0.7% | -0.5% | +0.3% | -0.3% | +0.7% |
| Jun 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $44.72 | $45.52 | +1.8% | +1.3% | +5.5% | +5.5% | +5.2% | -6.4% |
| Jun 26 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $65.12 | $65.36 | +0.4% | -25.9% | -25.6% | -27.3% | -31.3% | -30.5% |
| Jun 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $65.12 | $65.36 | +0.4% | -25.9% | -25.6% | -27.3% | -31.3% | -30.5% |
| Apr 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $34.48 | $38.24 | +10.9% | +2.1% | +0.5% | +5.3% | +3.0% | +8.4% |
| Apr 10 | Wedbush | Maintains | Outperform → Outperform | — | $39.28 | $41.60 | +5.9% | +2.0% | -2.4% | -7.9% | -10.8% | -12.2% |
| Feb 22 | JMP Securities | Maintains | Market Outperform → Outperform | — | $56.88 | $58.16 | +2.3% | +5.2% | +8.3% | +8.6% | +9.8% | +10.7% |
| Dec 9 | JP Morgan | Maintains | Overweight → Overweight | — | $38.24 | $40.88 | +6.9% | +3.1% | -2.3% | +23.4% | +32.0% | +46.9% |
| Aug 9 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $84.80 | $83.12 | -2.0% | -2.9% | +1.2% | +0.7% | +11.1% | +22.2% |
| Mar 16 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $69.12 | $69.92 | +1.2% | -4.4% | -0.5% | -4.2% | -10.6% | -12.5% |
| Feb 22 | JMP Securities | Maintains | Market Outperform → Outperform | — | $103.28 | $107.60 | +4.2% | -9.1% | -12.9% | -12.6% | -10.3% | -14.9% |
| Aug 23 | Evercore ISI | Maintains | Outperform → Outperform | — | $101.52 | $107.20 | +5.6% | +1.5% | +3.2% | +1.1% | +3.5% | +2.4% |
| Aug 23 | Jefferies | Maintains | Buy → Buy | — | $101.52 | $107.20 | +5.6% | +1.5% | +3.2% | +1.1% | +3.5% | +2.4% |
| Aug 23 | Cowen & Co. | Maintains | Outperform → Outperform | — | $101.52 | $107.20 | +5.6% | +1.5% | +3.2% | +1.1% | +3.5% | +2.4% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| May 5, 2026 | ADAR1 Capital Management, LLC10% | — | Buy | 35,101 | $14.00 | $491K | 779,784 | +0.69% | — |
| May 4, 2026 | ADAR1 Capital Management, LLC10% | — | Buy | 116,904 | $13.97 | $1.6M | 744,683 | +0.69% | — |
| May 4, 2026 | ADAR1 Capital Management, LLC10% | — | Buy | 3,900 | $13.90 | $54K | 627,779 | +0.69% | — |
8-K · 1.02
!! High
Rallybio Corporation -- 8-K 1.02: Material Agreement Terminated
I cannot determine the specific reason for termination (breach, mutual, regulatory, or expiration) from the information provided, so I'm unable to write the requested sentence accurately without speculating.
May 4
S-4
!!! Very High
Rallybio Corporation -- Merger Registration
Rallybio Corporation shareholders will receive a name change to Candid Therapeutics, Inc. upon completion of a merger transaction.
Apr 24
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
An executive departure at Rallybio signals potential leadership instability and warrant expiration within 90 days post-merger, which could pressure stock price and dilute shareholder value.
Mar 31
S-4
!!! Very High
Unknown — Merger Registration
Rallybio is merging with an unknown entity, likely resulting in significant changes to ownership structure and stock terms that existing shareholders must evaluate for dilution and value implications.
Mar 17
8-K
Rallybio Corporation -- 8-K Filing
Rallybio's merger with Candid will convert Candid option holders' shares into Rallybio options, with final ownership percentages dependent on Rallybio's cash position at closing.
Mar 2
Data updated apr 26, 2026 11:03pm
· Source: massive.com